VETARYS and Antigenesis Biologics Partner on Canine Cancer

The companies are collaborating to develop a new subcutaneous immunotherapy fusion protein for dogs with solid tumors.

Updated on Oct. 26, 2026 in Veterinary Medicine

Bold vector editorial illustration showing two amber glass medical vials on a sterile steel surface, reflecting pharmaceutical research. — VETARYS and Antigenesis Biologics are collaborating on a new subcutaneous immunotherapy fusion protein intended to treat solid tumors in dogs. AI Illustration. Upload story photo >

Live Poll

Would you support the use of human-derived immunotherapy treatments for your own pets?

VETARYS and Antigenesis Biologics have launched a research collaboration to create a combination immunotherapy for solid tumors in dogs. The therapy, designed as a fusion protein, is intended for administration by primary care veterinarians.

Why it matters

The development aims to address the current shortage of veterinary oncology specialists and provide an alternative to traditional radiation and chemotherapy. These standard treatments often involve variable efficacy and significant side effects for canine patients.

The proposed therapy is a subcutaneous treatment currently being developed as a fusion protein that combines two distinct immunotherapies. Antigenesis Biologics is utilizing its platform to adapt existing human immunotherapies for companion animals.

The players

VETARYS, Inc.

This biotechnology company, formerly known as VetrixBio, focuses on developing advanced veterinary medical treatments.

Antigenesis Biologics

This organization specializes in adapting human immunotherapy research to create antibody-based therapeutics for companion animals.

The details

The treatment is designed specifically for subcutaneous delivery, which would allow primary care veterinarians to administer the drug without referring pets to oncology specialists. VETARYS, formerly known as VetrixBio, has secured an option for an exclusive license to the final canine combination immunotherapy product.

October 26, 2026: VETARYS announced the partnership at the Boston Animal Health Nutrition and Technology Innovation Conference.

Culture Shift

This collaboration reflects a broader trend of expanding the scope of primary care veterinary medicine through biotechnology. By shifting complex oncological treatments from specialty clinics to local veterinary offices, the industry aims to bridge gaps in accessible animal cancer care.

Pet owners may eventually gain access to advanced cancer immunotherapy directly at their local veterinarian's office rather than needing a referral to a specialist. This could significantly reduce the logistical burden and costs associated with treating solid tumors in dogs.

The takeaway

This collaboration highlights the growing use of fusion proteins to simplify complex veterinary treatments. Dog owners should consult with their regular veterinarian about emerging oncology options as these new delivery methods become available for clinical use.